News
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
2024 nominations are open for Giants of Cancer Care®
Share your views with OncChats
Specialty
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
OncClub
All Oncology News
Pipeline Report
Insights
Medical World News
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conference Coverage
Conference Listing
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
OncologyLive
Oncology Fellows
Supplements And Featured Publications
All Publications
CME/CE
Interactive Tools
Learning Modules
Presentations
Sponsored
Print Subscription
eNewsletter
Advertisement
Urothelial Cancer
| Breast Cancer
| Lung Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Ovarian Cancer
| Prostate Cancer
| Melanoma & Skin Cancer
| Mantle Cell Lymphoma
| Myeloproliferative Neoplasms
| Biosimilars
| Brain Cancer
| Business Management
| CAR T-cell Therapy
| COVID-19
| Chronic Lymphocytic Leukemia
| Colorectal Cancer
| Disparities in Cancer Care
| Global Oncology
| Gynecologic Oncology
| Head & Neck Cancers
| Hematologic Oncology
| Immuno-Oncology
| Multiple Myeloma
| Neoadjuvant HER2+
| Non-Hodgkin Lymphoma
| Oncology Nursing News
| Pediatric Oncology
| Precision Medicine in Oncology®
| Sarcomas/TGCT
| Supportive Care
View All >>
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
  • Business Management
  • CAR T-cell Therapy
  • COVID-19
  • Chronic Lymphocytic Leukemia
  • Colorectal Cancer
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Global Oncology
  • Gynecologic Oncology
  • Head & Neck Cancers
  • Hematologic Oncology
  • Immuno-Oncology
  • Lung Cancer
  • Mantle Cell Lymphoma
  • Melanoma & Skin Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Neoadjuvant HER2+
  • Non-Hodgkin Lymphoma
  • Oncology Nursing News
  • Ovarian Cancer
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Prostate Cancer
  • Sarcomas/TGCT
  • Supportive Care
  • Urothelial Cancer

SPOTLIGHT -

2024 nominations are open for Giants of Cancer Care®
| Share your views with OncChats
Medullary Thyroid Cancer: Advances and Challenges : Episode 10

Treatment-Related Toxicity in Advanced MTC

Jul 16, 2013

For High-Definition, Click

Unique side effects are associated with each drug approved to treat patients with metastatic medullary thyroid cancer (MTC). As antiangiogenic agents, both vandetanib and cabozantinib are associated with hypertension, diarrhea, intestinal perforations, and tracheal esophageal fistula, notes Steven I. Sherman, MD. These side effects should be managed closely, particularly since diarrhea is already associated with MTC.

There is a risk for QT interval prolongation for patients treated with vandetanib, points out Sherman. As a result, patients treated with this drug should be monitored closely by electrocardiogram. Additionally, vandetanib is associated with cutaneous side effects, mucositis, rash, and photosensitivity.

As a result of these toxicities, not all patients are candidates for treatment. For stable patients, active surveillance should be utilized, suggests R. Michael Tuttle, MD. However, for rapidly progressive disease, the benefits of aggressive treatment may outweigh the risks.

The final decision about whether to administer cabozantinib or vandetanib should include input from a multidisciplinary team and can be individualized based on the patient's preference, specifically in the case of borderline progressive and stable disease, notes Lori J. Wirth, MD. These drugs may be warranted, for patients with 2 cm metastatic lesions that grow by 25% of more over the course of a year, believes Sherman.

Related Videos
In this first episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, and Michael W. McDermott, MD, explain how low-intensity focused ultrasound works and the rationale for examining its use in cancer and other conditions.
Jun Ma, MD
Bernard Doger de Spéville, MD, PhD
Experts on DTC
Experts on DTC
Experts on DTC
Dana B Cardin, MD, MSCI
Experts on DTC
Experts on DTC
Expert on DTC
Related Content

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

May 31st 2023

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

May 31st 2023

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

May 31st 2023
Related Content
David P. Carbone, MD, PhD

Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma

June 6th 2023
Article
Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021
Podcast
Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023
Article
Gordan on Growing the Infrastructure for In-House Genomic Testing

Gordan on Growing the Infrastructure for In-House Genomic Testing

October 14th 2021
Podcast
Jane Meisel, MD

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023
Article
The FDA has approved olaparib (Lynparza) plus abiraterone and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.

FDA Approves Olaparib/Abiraterone Combo for BRCA+ Metastatic Castration-Resistant Prostate Cancer

May 31st 2023
Article

Latest Conference Coverage

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

Acalabrutinib and Zanubrutinib Produce Similar PFS in a Matching-Adjusted Indirect Comparison in R/R CLL

Nivolumab Plus Relatlimab Demonstrates Consistent Benefit for Patients with Advanced Melanoma

Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact